Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4‐Thiadiazole‐Based Compounds as EGFR Inhibitors

Documenti analoghi

• Design, Synthesis and Molecular Docking of New Thieno[2,3‑d]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors
  di: Sara Sultan, et al.
  Pubblicazione: (2025)
• Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP‐1/EGFR Inhibitors
  di: Haytham O. Tawfik, et al.
  Pubblicazione: (2026)
• Exploring Novel Tetrahydropyrimidine and Fused Pyrimidine‐Based Compounds as DHFR Inhibitors and Antimicrobial Agents: Synthesis, In Vitro, In Vivo, and In Silico Studies
  di: Menna M. Sherif, et al.
  Pubblicazione: (2025)
• Structure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
  di: Ahmet Bugra Aksel, et al.
  Pubblicazione: (2026)
• Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights
  di: Ahmed K. B. A. W. Farouk, et al.
  Pubblicazione: (2026)